Skip to main content
SpringerLink
Log in

Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Patients with type 2 diabetes (T2D) manifest significant abnormalities in lipoprotein structure and function. The deleterious impact of oxidative and glycoxidative modifications on HDL-mediated atheroprotective, antiinflammatory, and antioxidative phenomena has been well established. However, the biological effects of modified HDL on adrenal steroidogenesis—which could reveal a pathophysiological link to the overactivity of the renin–angiotensin–aldosterone system and its adverse cardiovascular consequences often observed in T2D—are not well delineated. We studied the role of modified HDL on aldosterone release from adrenocortical carcinoma cells (NCI-H295R). In vitro modifications of native HDL were performed in the presence of glucose for glycoxidized HDL (glycoxHDL) and sodium hypochlorite for oxidized HDL. Angiotensin II (AngII)-sensitized H295R cells were treated with lipoproteins for 24 h, and supernatant was used to measure aldosterone release. Both native and modified HDL augmented the steroid release from AngII-sensitized cells, with glycoxHDL having the greatest impact. Both the modified forms of HDL induced a significant increase in scavenger receptor expression and employed protein kinase C as well as extracellular signal-regulated kinase as downstream effectors of aldosterone release. Native HDL and modified HDL required Janus kinase-2 for combating increased demand in steroidogenesis. Therefore, our data support the hypothesis that diabetes-induced modification of HDL may promote adrenocortical aldosterone secretion via different signal transduction pathways. This significant influence on multiple signaling mechanisms could be targeted for future research to implement novel therapeutic trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sviridov D, Nestel P (2002) Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 161(2):245–254

    Article  PubMed  CAS  Google Scholar 

  2. Gotto AM, Brinton EA Jr (2004) Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. J Am Coll Cardiol 43:717–724

    Article  PubMed  CAS  Google Scholar 

  3. Kontush A, Chapman JM (2006) Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 58:342–374

    Article  PubMed  CAS  Google Scholar 

  4. Azhar S, Leers-Sucheta S, Reaven E (2003) Cholesterol uptake in adrenal and gonadal tissues: the SR-BI and ‘selective’ pathway connection. Front Biosci 8:s998–s1029

    Article  PubMed  Google Scholar 

  5. Hu J, Zhang Z, Shen WJ, Azhar S (2010) Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab 7(47):1–25

    Google Scholar 

  6. Cherradi N, Bideau M, Arnaudeau S, Demaurex N, James RW, Azhar S et al (2001) Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I. Endocrinology 142:4540–4549

    Article  PubMed  CAS  Google Scholar 

  7. Krug AW, Kopprasch S, Ziegler CG, Dippong S, Catar RA, Bornstein SR et al (2007) Aldosterone rapidly induces leukocyte adhesion to endothelial cells: a new link between aldosterone and arteriosclerosis? Hypertension 50:e156–e157

    Article  PubMed  CAS  Google Scholar 

  8. Krug AW, Ehrhart-Bornstein M (2008) Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51:1252–1258

    Article  PubMed  CAS  Google Scholar 

  9. Fujita T (2008) Aldosterone in salt sensitive hypertension and metabolic syndrome. J Mol Med 86:729–734

    Article  PubMed  CAS  Google Scholar 

  10. Henriksen EJ (2007) Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 293:R974–R980

    Article  PubMed  CAS  Google Scholar 

  11. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med 353:2643–2653

    Article  PubMed  Google Scholar 

  12. Graessler J, Pietzsch J, Westendorf T, Julius U, Bornstein SR, Kopprasch S (2007) Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor γ gene expression in macrophages. Diabetologia 50:1080–1088

    Article  PubMed  CAS  Google Scholar 

  13. Veiraiah A (2005) Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology 56:431–438

    Article  PubMed  Google Scholar 

  14. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J et al (2000) Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243–2247

    Article  PubMed  CAS  Google Scholar 

  15. Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktchiev T, Hanefeld M et al (2002) In vivo evidence of increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 51:3102–3106

    Article  PubMed  CAS  Google Scholar 

  16. Ansurudeen I, Pietzsch J, Graessler J, Ehrhart-Bornstein M, Saha S, Bornstein SR et al (2010) Modulation of adrenal aldosterone release by oxidative modification of low-density lipoprotein. Am J Hypertens 23(10):1061–1068

    Article  PubMed  CAS  Google Scholar 

  17. Kopprasch S, Pietzsch J, Ansurudeen I, Graessler J, Krug AW, Ehrhart-Bornstein M et al (2009) Prediabetic and diabetic in vivo modification of circulating low density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion. J Endocrinol 200:45–52

    Article  PubMed  CAS  Google Scholar 

  18. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O’Brien R et al (2007) Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50(8):1770–1779

    Article  PubMed  CAS  Google Scholar 

  19. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F et al (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 50(3):643–653

    Article  PubMed  CAS  Google Scholar 

  20. Mastorikou M, Mackness B, Liu Y, Mackness M (2008) Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med 25:1049–1055

    Article  PubMed  CAS  Google Scholar 

  21. Goodfriend TL, Egan B, Stepniakowski K, Ball DL (1995) Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 25:30–36

    PubMed  CAS  Google Scholar 

  22. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48:239–245

    Article  PubMed  CAS  Google Scholar 

  23. Fallo F, Veglio F, Bertello C, Sonino N, Della MP, Ermani M et al (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91:454–459

    Article  PubMed  CAS  Google Scholar 

  24. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS et al (2005) Clinical and genetic correlates of serum aldosterone in the community: the Framingham heart study. Am J Hypertens 18:657–665

    Article  PubMed  CAS  Google Scholar 

  25. Xing Y, Cohen A, Rothblat G, Sankaranarayanan S, Weibel G, Royer L et al (2011) Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2). Endocrinology 152:751–763

    Article  PubMed  CAS  Google Scholar 

  26. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M (1995) Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1254:77–88

    PubMed  Google Scholar 

  27. Maeba R, Shimasaki H, Ueta N (1994) Conformational changes in oxidized LDL recognized by mouse peritoneal macrophages. Biochim Biophys Acta 1215:79–86

    PubMed  CAS  Google Scholar 

  28. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464–478

    Article  PubMed  CAS  Google Scholar 

  29. Yagi K (1976) A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15:212–216

    Article  PubMed  CAS  Google Scholar 

  30. Laemmly UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685

    Article  Google Scholar 

  31. Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN (2009) Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 202:162–168

    Article  PubMed  CAS  Google Scholar 

  32. Braschi S, Geoffrion M, Nguyen A, Gaudreau Y, Milne RW (2006) The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients. Diabetologia 49:1394–1401

    Article  PubMed  CAS  Google Scholar 

  33. Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN (2008) Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 19(4):378–384

    Article  PubMed  CAS  Google Scholar 

  34. Nieland TJF, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T et al (2004) Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J Lipid Res 45:1256–1265

    Article  PubMed  CAS  Google Scholar 

  35. Osada Y, Shiratsuchi A, Nakanishi Y (2006) Involvement of mitogen activated protein kinases in class B scavenger receptor I-induced phagocytosis of apoptotic cells. Exp Cell Res 312(10):1820–1830

    Article  PubMed  CAS  Google Scholar 

  36. Marshall CJ (1994) MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 4(1):82–89

    Article  PubMed  CAS  Google Scholar 

  37. Mendez AJ, Oram JF, Bierman EL (1991) Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem 266(16):10104–10111

    PubMed  CAS  Google Scholar 

  38. Tian Y, Smith RD, Balla T, Catt KJ (1998) Angiotensin II activates mitogen-activated protein kinase via protein kinase C and Ras/Raf-1 kinase in bovine adrenal glomerulosa cells. Endocrinology 139(4):1801–1809

    Article  PubMed  CAS  Google Scholar 

  39. Nofer JR, Fobker M, Höbbel G, Voss R, Wolinska I, Tepel M et al (2000) Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid: involvement in mitogenesis but not in cholesterol efflux. Biochemistry 39:15199–151207

    Article  PubMed  CAS  Google Scholar 

  40. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630–1635

    Article  PubMed  CAS  Google Scholar 

  41. Li J, Feltzer RE, Dawson KL, Hudson EA, Clark BJ (2003) Janus kinase 2 and calcium are required for angiotensin II-dependent activation of steroidogenic acute regulatory protein transcription in H295R human adrenocortical cells. J Biol Chem 278(52):52355–52362

    Article  PubMed  CAS  Google Scholar 

  42. Leung PS, Carlsson PO (2001) Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 26(3):155–164

    Article  PubMed  CAS  Google Scholar 

  43. Chu YK, Leung PS (2009) Angiotensin II in type 2 diabetes mellitus. Curr Protein Pept Sci 10:75–84

    Article  PubMed  CAS  Google Scholar 

  44. Willenberg HS, Schinner S, Ansurudeen I (2008) New mechanisms to control aldosterone synthesis. Horm Metab Res 40:435–441

    Article  PubMed  CAS  Google Scholar 

  45. Brunham LR, Kruit JK, Verchere CB, Hayden MR (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118:403–408

    Article  PubMed  CAS  Google Scholar 

  46. Klein RL, Laimins M, Lopes-Virella MF (1995) Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 44(9):1093–1098

    Article  PubMed  CAS  Google Scholar 

  47. Thorne RF, Mhaidat NM, Ralston KJ, Burns GF (2007) CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. Fed Eur Biochem Soc 581(6):1227–1232

    Article  CAS  Google Scholar 

  48. Pilon A, Martin G, Bultel-Brienne S, Junquero D, Delhon A, Fruchart JC et al (2003) Regulation of scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochemica et Biophysica Acta 1631:218–228

    CAS  Google Scholar 

  49. Martinat N, Crépieux P, Reiter E, Guillou F (2005) Extracellular signal-regulated kinases (ERK)1, 2 are required for luteinizing hormone (LH)-induced steroidogenesis in primary Leydig cells and control steroidogenic acute regulatory (StAR) expression. Reprod Nutr Dev 45:101–108

    Article  PubMed  CAS  Google Scholar 

  50. Ansurudeen I, Willenberg HS, Kopprasch S, Krug AW, Ehrhart-Bornstein M, Bornstein SR (2009) Endothelial factors mediate aldosterone release via PKA-independent pathways. Mol Cell Endocrinol 300(1–2):66–70

    Article  PubMed  CAS  Google Scholar 

  51. Grewal T, de Diego I, Kirchhoff MF, Tebar F, Heeren J, Rinninger F et al (2003) High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem 278:16478–16481

    Article  PubMed  CAS  Google Scholar 

  52. Foster RH (2004) Reciprocal influences between the signalling pathways regulating proliferation and steroidogenesis in adrenal glomerulosa cells. J Mol Endocrinol 32(3):893–902

    Article  PubMed  CAS  Google Scholar 

  53. Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic β cells. Endocrinology 150(10):4521–4524

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The authors thank Martina Kohl, Sigrid Nitzsche, and Eva Schubert for their excellent technical support. This work was supported by the Deutsche Forschungsgemeinschaft (KFO 252 to SRB).

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Fetscherstraße 74, 01307, Dresden, Germany

    Sarama Saha, Juergen Graessler, Peter E. H. Schwarz, Claudia Goettsch, Stefan R. Bornstein & Steffi Kopprasch

Authors
  1. Sarama Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juergen Graessler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter E. H. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Goettsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan R. Bornstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steffi Kopprasch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarama Saha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saha, S., Graessler, J., Schwarz, P.E.H. et al. Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways. Mol Cell Biochem 366, 1–10 (2012). https://doi.org/10.1007/s11010-012-1274-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-012-1274-2

Keywords

Search

Navigation